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Mitochondria play key roles in regulating the ageing 
process. When their membrane potential and function 
declines, their production of adenosine triphosphate 
(ATP) reduces and they can signal cell death. This is 
particularly marked in the energy demanding central 
nervous system, where the neurons and glia, undergo 
some key structural and functional changes during 
ageing. For the neurons, there is a progressive decline 
in their numbers, due to an intrinsic accumulation of 
aberrant proteins and free radicals, genetic mutations 
and/or mitochondrial defects [1, 2]. The glial cells, by 
contrast, undergo a striking increase in their number 
and activity, reflective of an inflammatory response 
due to the loss of neurons (Lynch et al. 2010). Over 
the years, many have sought ways to alter the course 
of these cellular changes, to slow the ageing process 
and improve quality of later. From genetic mani-
pulations to changes in diet and from using pharma-
ceuticals and antioxidants to incorporating more 
exercise and lowering cardiovascular risk factors, all 
have attempted to extend life and reduce the adverse 
impact of age [1, 2]. 
Recently, photobiomodulation, the application of red to 
infrared light (λ=600-1000nm) on body tissues has been 
reported to alter the course of aged decline. These 
wavelengths are absorbed by cytochrome c oxidase, the 
rate limiting enzyme in mitochondrial respiration, 
increasing its activity along with mitochondrial 
membrane potential and ATP production [3, 4] (Karu 
2010; Gkotsi et al.  2014). For the neurons, photobio-
modulation improves function, as measured by electro-
retinograms, in the retina of aged mice (Sivapathasun-
tharam et al. 2017), together with reducing cell death in 
a range of experimental pathologies in the brain [4-7]. 
For the glial cells, photobiomodulation reduces their 
hyperactivity, by decreasing their proliferation and 
levels of key structural proteins associated with decline 
(eg, vimentin, GFAP), oxidative stress (eg, acrolein) 
and inflammation (eg, α-tumour necrosis factor, 
complement component C3) in the retina [3] (Begum et 
al. 2013; Gkotsi et al. 2014; Sivapathasuntharam et al. 
2017) and brain (El Massri et al. 2018) of aged mice. 
The precise mechanisms used by photobiomodulation 
are unclear. Mitochondrial and physiological functions 
are improved, but increased ATP production alone is 
unlikely to underpin the physiological improvement, as 
this is relatively temporary. Hence, there are likely to be                                                          








cascades of signalling between mitochondria and other 
structures including the nucleus and endoplasmic reticu-
lum that have a wide ranging impact on metabolism that 
sustain longer term positive changes. For the neurons, 
several studies have reported that photobiomodulation 
activates various transcription factors leading to the 
expression of stimulatory and protective genes related 
to beneficial cellular features, for example neuro-
genesis, synaptogenesis and an increase in neurotrophic 
growth factors [4]. For the glial cells, the mechanisms 
are less clear. Photobiomodulation-induced reductions 
in hyperactivity may be secondary to the beneficial 
effects seen in neurons, but there could be a primary 
effect also, that photobiomodulation stimulates glial 
cells directly to reduce the inflammatory response (El 
Massri et al. 2018). 
A key issue for consideration at this point is whether the 
photobiomodulation-induced benefits seen in the animal 
models of ageing can be translated to humans. One 
problem would be method of application, given the 
large size of the human brain. Photobiomodulation has 
been reported to penetrate 20-30mm through a range of 
body tissues, from bone to brain [4-6]. Hence, from a 
transcranial approach, photobiomodulation would only 
reach cortical layers of the brain (<10mm), but it would 
penetrate the retina. For deeper structures of the brain 
(>30mm), such as the brainstem and hypothalamus, 
photobiomodulation may mediate benefits indirectly via 
the circulation, perhaps via cytokine signalling [5, 6]. 
There is evidence that changes in mitochondrial func-
tion in one part of the body can influence those at other 
locations, and improvements in retinal pathology have 
been reported after photobiomodulation treatment away 
from the eyes [8]. However, data here are very limited. 
In conclusion, photobiomodulation has been shown to 
alter the course of ageing in the central nervous system, 
by improving the survival and function of neurons and 
reducing gliosis and inflammation. These results in the 
laboratory are ripe for translation to the clinic, to 
determine whether this treatment effectively slows 
ageing in humans. Some of the key advantages of 
photobiomodulation therapy relate to its economy and 
safety, as it can be delivered with commercially 
available light emitting devices at energies well within 
the human safety range. Moreover, a major strength of 
this therapy is that it can offer a potential clinical 
application where there is little alternative available. 
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